Belgian atopic dermatitis guidelines

Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and trea... Mehr ...

Verfasser: Hilde Lapeere
Reinhart Speeckaert
Marie Baeck
Bita Dezfoulian
Julien Lambert
Pierre-Paul Roquet-Gravy
Annelies Stockman
Jonathan White
Francisca Castelijns
Jan Gutermuth
Dokumenttyp: Dataset
Erscheinungsdatum: 2023
Schlagwörter: Medicine / Biotechnology / Ecology / Sociology / Developmental Biology / Science Policy / Hematology / Biological Sciences not elsewhere classified / Atopic dermatitis / diagnosis / therapy / guideline / eczema
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-26919285
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.6084/m9.figshare.24631847.v1

Atopic dermatitis (AD) is one of the most common, bothersome and difficult to treat skin disorders. Recent introduction of new systemic treatments has revolutionized the management of AD. The goal of this guideline is to provide evidence-based recommendations for the management of patients suffering from atopic dermatitis that easily can be implemented in clinical practice. These recommendations were developed by 11 Belgian AD experts. Comments of all experts on the proposed statements were gathered, followed by an online voting session. The most relevant strategies for the management and treatment of AD in the context of the Belgian health care landscape are discussed. General measures, patient education and adequate topical treatment remain the cornerstones of AD management. For moderate to severe AD, the introduction of biologics and JAK inhibitors show unprecedented efficacy, although currently access is limited to a subgroup of patients meeting the reimbursement criteria.